Publisher Correction: Analyzing bacterial networks and interactions in skin and gills of Sparus aurata with microalgae-based additive feeding. [PDF]
Cerezo IM+6 more
europepmc +1 more source
Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study
ABSTRACT Objective Identifying functional measures that are both valid and reliable in the limb girdle muscular dystrophy (LGMD) population is critical for quantifying the level of functional impairment related to disease progression in order to establish clinical trial readiness in the context of anticipated therapeutic trials.
Stephanie M. Hunn+29 more
wiley +1 more source
Comment on 'bibliometric insights into systemic sclerosis with renal involvement: trends, contributions, and future directions'. [PDF]
Chen Y, Zhang J.
europepmc +1 more source
ABSTRACT Objective To investigate the reliability of very high‐frequency oscillations (VHFOs, 500–2000 Hz) as biomarkers in identifying the epileptogenic zone (EZ) in mesial temporal lobe epilepsy (MTLE) patients. Methods We reviewed 19 MTLE patients who underwent stereo‐electroencephalography‐guided radiofrequency thermocoagulation.
Stéphane Jean+10 more
wiley +1 more source
Microstructural and microvascular features of white matter hyperintensities and their association with small vessel disease markers. [PDF]
Wang LL+9 more
europepmc +1 more source
ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib+16 more
wiley +1 more source
Lithospheric features revealed by a new Moho map in the central-western Sicily Channel. [PDF]
Bongiovanni S+4 more
europepmc +1 more source
ABSTRACT This study assessed whether continued treatment with anti‐CGRP monoclonal antibodies (mAbs) is driven more by reductions in monthly migraine days (MMDs) or patients' global impression of change (PGIC), a patient‐reported outcome. Among 169 patients treated with anti‐CGRP mAbs, 21.3% discontinued due to ineffectiveness. PGIC responders (≥ 5) at
Marina Romozzi+4 more
wiley +1 more source
Invited commentary: target trial emulation-a call for more widespread use. [PDF]
Anderson AH.
europepmc +1 more source